Biodexa Pharmaceuticals Plc (BDRX) Balance Sheet
BDRX balance sheet, 2025
December 31, 2025 · British pounds£18.1M assets = £6.8M liabilities + £11.4M equity
Both columns are drawn to the same scale: what BDRX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BDRX financial health
Descriptive bands, not a rating. Fiscal 2025.
BDRX balance sheet trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | £30.9M2019 | £18.1M2025 | −8.5%/yr | |
| Total liabilities | £11.3M2019 | £6.8M2025 | −8.3%/yr | |
| Shareholders’ equity | £19.6M2019 | £11.4M2025 | −8.6%/yr | |
| Cash & short-term investments | £10.9M2019 | £8.5M2025 | −4.1%/yr | |
| Total debt | £6.1M2019 | £60,8922025 | −53.6%/yr | |
| Net cash (debt) | £4.8M2019 | £8.5M2025 | +£3.6M | |
| Working capital | £8.1M2019 | £6.3M2025 | −£1.8M | |
| Current ratio | 2.422019 | 2.032025 | −0.39 | |
| Debt / equity | 0.312019 | 0.012025 | −0.31 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BDRX assets
BDRX liabilities and equity
BDRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BDRX balance sheet in British pounds
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | £8.5M | £1.7M | £6.0M | £2.8M | £10.1M | £7.5M | £10.9M |
| Cash & equivalents | £8.5M | £1.7M | £6.0M | £2.8M | £10.1M | £7.5M | £10.9M |
| Receivables | £221,609 | £715,000 | £704,000 | £329,000 | £33,000 | £95,000 | £1.8M |
| Inventory | £0 | £0 | −£704,000 | £1 | £1 | −£1.4M | £1 |
| Other current assets | £3.7M | £6.4M | £1.1M | £1.5M | £1.7M | £3.0M | £997,999 |
| Total current assets | £12.4M | £8.8M | £7.0M | £4.7M | £11.8M | £9.3M | £13.7M |
| Property, plant & equipment (net) | £90,839 | £324,000 | £571,000 | £831,000 | £1.2M | £542,000 | £2.2M |
| Goodwill & intangible assets | £5.6M | £5.6M | £2.9M | £6,000 | £0 | £0 | £12.4M |
| Long-term investments | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Other non-current assets | £2 | £0 | £0 | £0 | £0 | £0 | £2.6M |
| Total assets | £18.1M | £14.8M | £10.5M | £5.5M | £12.9M | £9.8M | £30.9M |
| Liabilities | |||||||
| Accounts payable | £97,000 | £707,000 | £314,000 | £339,000 | £485,000 | £337,000 | £725,000 |
| Short-term debt | £61,000 | £609,000 | £169,000 | £161,000 | £146,000 | £200,000 | £412,000 |
| Deferred revenue | £569,995 | £1.5M | £926,000 | £197,000 | — | £68,000 | — |
| Total current liabilities | £6.1M | £5.0M | £5.6M | £1.9M | £1.8M | £3.0M | £5.7M |
| Long-term debt | £0 | £0 | £0 | £0 | £0 | £0 | £4.8M |
| Lease obligations | £61,000 | £727,000 | £464,000 | £624,000 | £766,000 | £153,000 | £1.1M |
| Other long-term liabilities | £643,866 | £1.4M | £295,000 | £463,000 | £619,531 | £110,000 | £912,000 |
| Total liabilities | £6.8M | £6.5M | £5.9M | £2.4M | £2.5M | £3.1M | £11.3M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | £14.1M | £6.7M | £1.2M | £108,343 | £98,468 | £63,000 | £23,000 |
| Retained earnings (deficit) | −£102.6M | −£150.4M | −£144.8M | −£135.3M | −£127.8M | −£122.4M | −£99.8M |
| Accumulated other comprehensive income | £1.2M | £53.0M | £61.5M | £53.0M | £53.0M | £54.7M | £53.5M |
| Total shareholders' equity | £11.4M | £8.3M | £4.7M | £3.2M | £10.5M | £6.7M | £19.6M |
| Key figures | |||||||
| Total debt | £60,892 | £727,000 | £464,000 | £624,000 | £766,000 | £260,000 | £6.1M |
| Net cash (debt) | £8.5M | £942,000 | £5.5M | £2.2M | £9.3M | £7.3M | £4.8M |
| Working capital | £6.3M | £3.8M | £1.5M | £2.8M | £9.9M | £6.3M | £8.1M |
| Tangible book value | £5.7M | £2.7M | £1.7M | £3.2M | £10.5M | £6.7M | £7.2M |
| Shares outstanding | 22K | — | — | — | — | — | — |
| Current ratio | 2.03 | 1.75 | 1.26 | 2.47 | 6.39 | 3.10 | 2.42 |
| Quick ratio | 1.43 | 0.47 | 1.20 | 1.67 | 5.48 | 2.56 | 2.25 |
| Debt / equity | 0.01 | 0.09 | 0.10 | 0.20 | 0.07 | 0.04 | 0.31 |
| Equity / assets | 62.7% | 56.3% | 44.4% | 57.2% | 80.9% | 68.4% | 63.3% |
| Jun '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | £3.2M | £8.5M | £4.0M | £1.7M | £1.7M | £5.1M | £5.1M | £6.0M | £6.0M | £5.2M | £5.2M | £2.8M |
| Cash & equivalents | £3.2M | £8.5M | £4.0M | £1.7M | £1.7M | £5.1M | £5.1M | £6.0M | £6.0M | £5.2M | £5.2M | £2.8M |
| Receivables | £3.4M | £221,609 | £4.5M | £715,000 | £715,000 | £1.9M | £1.9M | £704,000 | £0 | £2.0M | £903,000 | £329,000 |
| Inventory | £0 | £0 | £0 | £0 | £0 | £0 | £0 | −£704,000 | £0 | −£1.1M | £0 | £1 |
| Other current assets | £0 | £3.7M | £462,001 | £6.4M | £6.4M | £547,000 | £547,000 | £1.1M | £1.1M | £1.1M | £1.1M | £1.5M |
| Total current assets | £6.6M | £12.4M | £9.0M | £8.8M | £8.8M | £7.5M | £7.5M | £7.0M | £7.0M | £7.3M | £7.3M | £4.7M |
| Property, plant & equipment (net) | £19,879 | £90,839 | £187,000 | £324,000 | £324,000 | £436,000 | £436,000 | £571,000 | £571,000 | £693,000 | £693,000 | £831,000 |
| Goodwill & intangible assets | £6.0M | £5.6M | £5.6M | £5.6M | £5.6M | £6.0M | £6.0M | £2.9M | £2.9M | £5,000 | £5,000 | £6,000 |
| Long-term investments | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Other non-current assets | £2 | £2 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Total assets | £12.6M | £18.1M | £14.8M | £14.8M | £14.8M | £14.0M | £14.0M | £10.5M | £10.5M | £8.0M | £8.0M | £5.5M |
| Liabilities | ||||||||||||
| Accounts payable | — | £97,000 | £1.4M | £707,000 | £707,000 | £1.7M | £1.7M | £314,000 | £314,000 | £1.8M | £1.8M | £339,000 |
| Short-term debt | — | £121,892 | £501,000 | £609,000 | £609,000 | £348,000 | £174,000 | £169,000 | £169,000 | £164,000 | — | £161,000 |
| Deferred revenue | — | £571,000 | — | £1.5M | £1.5M | — | — | £926,000 | — | — | — | £197,000 |
| Total current liabilities | £2.8M | £6.1M | £2.5M | £5.0M | £5.0M | £3.5M | £3.5M | £5.6M | £5.6M | £2.3M | £2.3M | £1.9M |
| Long-term debt | £0 | £0 | £0 | £0 | £0 | £208,000 | £0 | £0 | £0 | £0 | £0 | £0 |
| Lease obligations | — | £61,000 | — | — | £727,000 | — | — | £464,000 | — | £544,000 | — | £624,000 |
| Other long-term liabilities | £329,000 | £643,866 | £909,000 | £1.4M | £1.4M | £1.6M | £1.8M | £295,000 | £295,000 | £379,706 | £380,000 | £463,000 |
| Total liabilities | £3.1M | £6.8M | £3.4M | £6.5M | £6.5M | £5.2M | £5.2M | £5.9M | £5.9M | £2.7M | £2.7M | £2.4M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | £14.2M | £14.1M | £61,561 | £6.7M | £6.7M | £3.6M | £3.6M | £1.2M | £1.2M | £277,972 | £278,000 | £108,343 |
| Retained earnings (deficit) | −£104.0M | −£102.6M | −£154.1M | −£150.4M | −£150.4M | −£147.9M | −£147.9M | −£144.8M | −£144.8M | −£139.0M | −£139.0M | −£135.3M |
| Accumulated other comprehensive income | £172,949 | £1.2M | £67.8M | £53.0M | £53.0M | £61.7M | £61.7M | £53.0M | £61.5M | £53.0M | £59.3M | £54.7M |
| Total shareholders' equity | £9.6M | £11.4M | £11.4M | £8.3M | £8.3M | £8.7M | £8.7M | £4.7M | £4.7M | £5.3M | £5.3M | £3.2M |
| Key figures | ||||||||||||
| Total debt | — | £60,892 | £501,000 | £727,000 | £727,000 | £382,000 | £174,000 | £464,000 | £295,000 | £544,000 | £380,000 | £624,000 |
| Net cash (debt) | — | £8.5M | £3.5M | £942,000 | £942,000 | £4.7M | £4.9M | £5.5M | £5.7M | £4.7M | £4.8M | £2.2M |
| Working capital | £3.9M | £6.3M | £6.5M | £3.8M | £3.8M | £4.0M | £4.0M | £1.5M | £1.5M | £5.0M | £5.0M | £2.8M |
| Tangible book value | £3.6M | £5.7M | £5.8M | £2.7M | £2.7M | £2.7M | £2.7M | £1.7M | £1.7M | £5.3M | £5.3M | £3.2M |
| Shares outstanding | 15K | 90K | 10K | — | 62K | — | 328K | — | 1.3M | — | 248K | — |
| Current ratio | 2.41 | 2.03 | 3.63 | 1.75 | 1.75 | 2.16 | 2.16 | 1.26 | 1.26 | 3.18 | 3.18 | 2.47 |
| Quick ratio | 2.41 | 1.43 | 3.44 | 0.47 | 0.47 | 2.00 | 2.00 | 1.20 | 1.07 | 3.18 | 2.69 | 1.67 |
| Debt / equity | — | 0.01 | 0.04 | 0.09 | 0.09 | 0.04 | 0.02 | 0.10 | 0.06 | 0.10 | 0.07 | 0.20 |
| Equity / assets | 75.6% | 62.7% | 77.1% | 56.3% | 56.3% | 62.5% | 62.5% | 44.4% | 44.4% | 66.6% | 66.6% | 57.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in British pounds as reported (latest annual report filed March 27, 2026); data from EODHD.
BDRX financial position
At the end of fiscal 2025 (December 31, 2025), Biodexa Pharmaceuticals Plc had total assets of £18.1 million (up 22.8% from a year earlier), total liabilities of £6.8 million and shareholders' equity of £11.4 million. It held £8.5 million in cash and short-term investments against £0.1 million of debt, a net cash position of £8.5 million. Its current ratio was 2.03. In the latest quarter (ended June 30, 2026) total assets were £12.6 million and equity £9.6 million.
Related: BDRX income statement, BDRX cash flow statement, BDRX key metrics. See the BDRX stock overview for the latest quote and news.
BDRX balance sheet FAQ
What are Biodexa Pharmaceuticals Plc's total assets?
Biodexa Pharmaceuticals Plc reported total assets of £18.1 million at the end of fiscal 2025 (December 31, 2025), compared with £14.8 million a year earlier.
How much debt does Biodexa Pharmaceuticals Plc have?
Biodexa Pharmaceuticals Plc had £0.1 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.01.
How much cash does Biodexa Pharmaceuticals Plc have?
Biodexa Pharmaceuticals Plc held £8.5 million in cash and short-term investments at the end of fiscal 2025; with £0.1 million of debt that is net cash of £8.5 million.
What is Biodexa Pharmaceuticals Plc's book value?
Biodexa Pharmaceuticals Plc's shareholders' equity (book value) was £11.4 million at the end of fiscal 2025.
What is Biodexa Pharmaceuticals Plc's current ratio?
Biodexa Pharmaceuticals Plc had current assets of £12.4 million and current liabilities of £6.1 million, a current ratio of 2.03 (it can cover its short-term obligations).
How much goodwill does Biodexa Pharmaceuticals Plc have?
Biodexa Pharmaceuticals Plc carried £5.6 million of goodwill and intangible assets, 31.1% of total assets, at the end of fiscal 2025.